The United States Food & Drug Administration (USFDA) has reportedly granted its final approval for marketing Zydus Cadila’s anti-viral drug acyclovir. “Zydus Cadila has received the final approval from the USFDA to market acyclovir tablets,” the company said in a statement issued on August 20, 2014.
The approval has been granted for acyclovir tablets in strengths of 400 mg and 800 mg. According to IMS data, the sales of acyclovir tablets in 2014 is estimated at $55.8 million.
The approval has been granted for acyclovir tablets in strengths of 400 mg and 800 mg. According to IMS data, the sales of acyclovir tablets in 2014 is estimated at $55.8 million.